GlaxoSmithKline Seeks Increased Damages in Teva Pharmaceuticals Labeling Dispute
GlaxoSmithKline LLC is pressing a Delaware federal judge to enhance the $235 million damages award that was previously granted against Teva Pharmaceuticals USA Inc. by a jury in 2017. The case involved infringement related to the “skinny” labeling of a pharmaceutical product, and it has returned to district court for further consideration. This significant legal…